Patents Assigned to Famewave Ltd.
-
Publication number: 20260167717Abstract: Pharmaceutical compositions comprising anti-CEACAM1 mAbs, and their use in inhibition of NET-mediated activities, and in prevention and treatment of pathologies associated with these activities are provided and exemplified with the mAb CM24 that is also shown to effectively inhibit cancer cell migration and NET-induced platelet aggregation. Further presented is a prognostic method based on NET-biomarkers for use in patient selection and monitoring of treatment efficacy.Type: ApplicationFiled: November 9, 2023Publication date: June 18, 2026Applicant: FAMEWAVE LTD.Inventors: Hadas REUVENI, Tomer MEIRSON, Michael SCHICKLER
-
Publication number: 20240092934Abstract: Provided are methods and compositions comprising antibodies capable of specific binding to human CEACAM1 molecules, for treating and diagnosing cancer as well as assessing CEACAM1 expression in tumor infiltrating immune cells (TILs) in a biological sample obtained from a [cancer] subject.Type: ApplicationFiled: November 24, 2023Publication date: March 21, 2024Applicant: FAMEWAVE LTD.Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Rona ORTENBERG, Jacob SCHACHTER, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
-
Patent number: 11891453Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.Type: GrantFiled: September 29, 2020Date of Patent: February 6, 2024Assignee: FAMEWAVE LTD.Inventors: Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
-
Patent number: 11866509Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.Type: GrantFiled: May 18, 2020Date of Patent: January 9, 2024Assignee: FAMEWAVE LTD.Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
-
Patent number: 11427647Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.Type: GrantFiled: December 2, 2019Date of Patent: August 30, 2022Assignee: FAMEWAVE LTD.Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
-
Publication number: 20210070884Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.Type: ApplicationFiled: September 29, 2020Publication date: March 11, 2021Applicant: Famewave Ltd.Inventors: Gal MARKEL, Tehila BEN MOSHE, Yair SAPIR, Ilana MANDEL, Jacob SCHACHTER, Rona ORTENBERG
-
Publication number: 20200277398Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.Type: ApplicationFiled: May 18, 2020Publication date: September 3, 2020Applicant: Famewave Ltd.Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
-
Publication number: 20200216557Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.Type: ApplicationFiled: December 2, 2019Publication date: July 9, 2020Applicant: Famewave Ltd.Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
-
Patent number: 10550196Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.Type: GrantFiled: April 27, 2015Date of Patent: February 4, 2020Assignee: Famewave Ltd.Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
